HK1200723A1 - Pharmaceutical diagnostic - Google Patents

Pharmaceutical diagnostic Download PDF

Info

Publication number
HK1200723A1
HK1200723A1 HK15101259.7A HK15101259A HK1200723A1 HK 1200723 A1 HK1200723 A1 HK 1200723A1 HK 15101259 A HK15101259 A HK 15101259A HK 1200723 A1 HK1200723 A1 HK 1200723A1
Authority
HK
Hong Kong
Prior art keywords
amide
glutamine
pharmaceutical diagnostic
pi3k
thiazol
Prior art date
Application number
HK15101259.7A
Other languages
English (en)
Chinese (zh)
Inventor
Pascal Furet
Christine Fritsch
Sauveur-Michel Maira
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48083130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1200723(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1200723A1 publication Critical patent/HK1200723A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15101259.7A 2012-03-29 2013-03-27 Pharmaceutical diagnostic HK1200723A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261617284P 2012-03-29 2012-03-29
US61/617,284 2012-03-29
US201361767848P 2013-02-22 2013-02-22
US61/767,848 2013-02-22
PCT/EP2013/056600 WO2013144249A1 (en) 2012-03-29 2013-03-27 Pharmaceutical diagnostic

Publications (1)

Publication Number Publication Date
HK1200723A1 true HK1200723A1 (en) 2015-08-14

Family

ID=48083130

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101259.7A HK1200723A1 (en) 2012-03-29 2013-03-27 Pharmaceutical diagnostic

Country Status (25)

Country Link
US (1) US9795596B2 (enExample)
EP (1) EP2830621B1 (enExample)
JP (1) JP6224067B2 (enExample)
KR (1) KR20140138771A (enExample)
CN (1) CN104271136A (enExample)
AR (1) AR090544A1 (enExample)
AU (1) AU2013241752B2 (enExample)
BR (1) BR112014023530A2 (enExample)
CA (1) CA2866127A1 (enExample)
CL (1) CL2014002576A1 (enExample)
CO (1) CO7091176A2 (enExample)
EA (1) EA028984B1 (enExample)
EC (1) ECSP14025016A (enExample)
ES (1) ES2845560T3 (enExample)
GT (1) GT201400206A (enExample)
HK (1) HK1200723A1 (enExample)
IL (1) IL234658B (enExample)
IN (1) IN2014DN08970A (enExample)
MX (1) MX2014011682A (enExample)
NZ (1) NZ628596A (enExample)
PH (1) PH12014502168A1 (enExample)
SG (2) SG10201608001RA (enExample)
TW (1) TW201345525A (enExample)
WO (1) WO2013144249A1 (enExample)
ZA (1) ZA201405938B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014229240B2 (en) * 2013-03-15 2017-06-15 Novartis Ag Biomarkers of tumor pharmacodynamic response
EP3140427B1 (en) * 2014-05-09 2020-10-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors
KR102486126B1 (ko) * 2014-10-03 2023-01-09 노파르티스 아게 알펠리십을 포함하는 제약 조성물
US20180353515A1 (en) * 2015-12-03 2018-12-13 Novartis Ag Treatment of cancer with a pi3k inhibitor in a patient presselected for having a pik3ca mutation in the ctdna
WO2019199860A1 (en) * 2018-04-09 2019-10-17 The Research Foundation For The State University Of New York Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
US5169766A (en) 1991-06-14 1992-12-08 Life Technologies, Inc. Amplification of nucleic acid molecules
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP2307414A4 (en) 2008-07-07 2011-10-26 Xcovery Holding Co Llc SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Also Published As

Publication number Publication date
AU2013241752B2 (en) 2016-07-07
SG10201608001RA (en) 2016-11-29
US20150111927A1 (en) 2015-04-23
ES2845560T3 (es) 2021-07-27
AR090544A1 (es) 2014-11-19
ZA201405938B (en) 2015-11-25
BR112014023530A2 (pt) 2017-07-18
CN104271136A (zh) 2015-01-07
AU2013241752A1 (en) 2014-09-25
EP2830621B1 (en) 2020-10-21
EA028984B1 (ru) 2018-01-31
IL234658B (en) 2018-02-28
IN2014DN08970A (enExample) 2015-05-22
CL2014002576A1 (es) 2015-01-23
US9795596B2 (en) 2017-10-24
GT201400206A (es) 2017-09-28
EA201491787A1 (ru) 2015-01-30
KR20140138771A (ko) 2014-12-04
PH12014502168A1 (en) 2014-12-10
JP6224067B2 (ja) 2017-11-01
CO7091176A2 (es) 2014-10-21
TW201345525A (zh) 2013-11-16
JP2015514080A (ja) 2015-05-18
WO2013144249A1 (en) 2013-10-03
NZ628596A (en) 2015-10-30
CA2866127A1 (en) 2013-10-03
SG11201405169SA (en) 2014-10-30
MX2014011682A (es) 2015-01-22
ECSP14025016A (es) 2015-09-30
EP2830621A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
WO2012109624A3 (en) Monovalent and multivalent multispecific complexes and uses thereof
EP2679193A4 (en) Surgical robot system for performing surgery based on displacement information determined by the specification of the user, and method for controlling same
HK1200723A1 (en) Pharmaceutical diagnostic
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2012118813A3 (en) Anti-il-6 receptor antibodies and methods of use
WO2013010136A3 (en) Inhibitors of bruton's tyrosine kinase
WO2014028777A3 (en) Methods of treating a tauopathy
WO2009083009A3 (en) Monoclonal antibodies against cd32b
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
WO2010066803A3 (en) Human antibodies against human tissue factor
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
ZA200900788B (en) Manufacture,method,and use of active substance-releasing medical products for permanently keeping blood vessels open
WO2008058019A3 (en) Devices and methods for accessing and treating an aneurysm
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
WO2010144721A3 (en) Model systems and treatment regimes for treatment of neurological disease
WO2012003470A3 (en) Antibody formulations
WO2013158821A3 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
WO2008151749A3 (de) Aktivierbare diagnostische und therapeutische verbindung
WO2013083098A3 (en) Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
WO2012125981A3 (en) Raf kinase inhibitors
BR112013021860A2 (pt) anticorpo anti-tnfalpha humanizado
WO2017160699A3 (en) Method of preventing graft versus host disease